149 related articles for article (PubMed ID: 33452699)
1. Antiviral treatment for hepatitis C is associated with a reduced risk of atherosclerotic cardiovascular outcomes: A systematic review and meta-analysis.
Su X; Zhao X; Deng JL; Li SN; Du X; Dong JZ; Ma CS
J Viral Hepat; 2021 Apr; 28(4):664-671. PubMed ID: 33452699
[TBL] [Abstract][Full Text] [Related]
2. Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV-coinfected patients who achieved sustained virological response.
Leone S; Prosperi M; Costarelli S; Nasta P; Maggiolo F; Di Giambenedetto S; Saracino A; Di Pietro M; Gori A
Eur J Clin Microbiol Infect Dis; 2016 Sep; 35(9):1511-20. PubMed ID: 27272121
[TBL] [Abstract][Full Text] [Related]
3. Direct-Acting Antiviral Therapy for HCV Infection Is Associated With a Reduced Risk of Cardiovascular Disease Events.
Butt AA; Yan P; Shuaib A; Abou-Samra AB; Shaikh OS; Freiberg MS
Gastroenterology; 2019 Mar; 156(4):987-996.e8. PubMed ID: 30445009
[TBL] [Abstract][Full Text] [Related]
4. Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis.
Simmons B; Saleem J; Hill A; Riley RD; Cooke GS
Clin Infect Dis; 2016 Mar; 62(6):683-694. PubMed ID: 26787172
[TBL] [Abstract][Full Text] [Related]
5. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.
Ji F; Yeo YH; Wei MT; Ogawa E; Enomoto M; Lee DH; Iio E; Lubel J; Wang W; Wei B; Ide T; Preda CM; Conti F; Minami T; Bielen R; Sezaki H; Barone M; Kolly P; Chu PS; Virlogeux V; Eurich D; Henry L; Bass MB; Kanai T; Dang S; Li Z; Dufour JF; Zoulim F; Andreone P; Cheung RC; Tanaka Y; Furusyo N; Toyoda H; Tamori A; Nguyen MH
J Hepatol; 2019 Sep; 71(3):473-485. PubMed ID: 31096005
[TBL] [Abstract][Full Text] [Related]
6. Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance.
Huang CF; Yeh ML; Huang CI; Lin YJ; Tsai PC; Lin ZY; Chan SY; Chen SC; Yang HI; Huang JF; Lu SN; Dai CY; Jen CL; Yuan Y; L'Italien G; Wang LY; Lee MH; Yu ML; Chuang WL; Chen CJ
Oncotarget; 2017 Jul; 8(27):43925-43933. PubMed ID: 28159934
[TBL] [Abstract][Full Text] [Related]
7. Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis.
Bang CS; Song IH
BMC Gastroenterol; 2017 Apr; 17(1):46. PubMed ID: 28376711
[TBL] [Abstract][Full Text] [Related]
8. Direct-acting antiviral agents decrease haemoglobin A1c level in patients with diabetes infected with hepatitis C virus: A systematic review & meta-analysis.
Lapumnuaypol K; Pisarcik D; Putthapiban P; Sukhumthammarat W; Wijarnpreecha K; Thongprayoon C; Ungprasert P
Indian J Med Res; 2020 Dec; 152(6):562-567. PubMed ID: 34145095
[TBL] [Abstract][Full Text] [Related]
9. Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis.
Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T; Tanaka J
Liver Int; 2016 Jun; 36(6):817-26. PubMed ID: 26787002
[TBL] [Abstract][Full Text] [Related]
10. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection.
Mahale P; Engels EA; Li R; Torres HA; Hwang LY; Brown EL; Kramer JR
Gut; 2018 Mar; 67(3):553-561. PubMed ID: 28634198
[TBL] [Abstract][Full Text] [Related]
11. Sex Differences in Extrahepatic Outcomes After Antiviral Treatment for Hepatitis C.
Li J; Gordon SC; Zhou Y; Boscarino JA; Schmidt MA; Daida YG; Rupp LB; Trudeau S; Lu M;
Am J Gastroenterol; 2021 Mar; 116(3):576-583. PubMed ID: 33399360
[TBL] [Abstract][Full Text] [Related]
12. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
[TBL] [Abstract][Full Text] [Related]
13. Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis.
Cacoub P; Desbois AC; Comarmond C; Saadoun D
Gut; 2018 Nov; 67(11):2025-2034. PubMed ID: 29703790
[TBL] [Abstract][Full Text] [Related]
14. Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications.
Nahon P; Bourcier V; Layese R; Audureau E; Cagnot C; Marcellin P; Guyader D; Fontaine H; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Leroy V; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Dharancy S; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Benhamou Y; Pilette C; Silvain C; Christidis C; Capron D; Bernard-Chabert B; Zucman D; Di Martino V; Thibaut V; Salmon D; Ziol M; Sutton A; Pol S; Roudot-Thoraval F;
Gastroenterology; 2017 Jan; 152(1):142-156.e2. PubMed ID: 27641509
[TBL] [Abstract][Full Text] [Related]
15. Antiviral Treatment for Hepatitis C Is Associated With a Reduced Risk of Periprosthetic Joint Infection: A Meta-Analysis of Observational Studies.
Cheng T; Xu D; Yan Z; Ding C; Yang C; Zhang X
J Arthroplasty; 2022 Sep; 37(9):1870-1878. PubMed ID: 35483609
[TBL] [Abstract][Full Text] [Related]
16. Decreased circulating vitamin D reflects adverse outcomes of hepatitis C virus infection: A systematic review and meta-analysis.
Udomsinprasert W; Jittikoon J; Sukkho S; Pojarassangkul N; Sangroongruangsri S; Chaikledkaew U
J Infect; 2020 Oct; 81(4):585-599. PubMed ID: 32553842
[TBL] [Abstract][Full Text] [Related]
17. Impact of hepatitis C sustained viral response on cardiovascular diseases: a meta-analysis.
Lapumnuaypol K; Thongprayoon C; Wijarnpreecha K; Cheungpasitporn W
Hosp Pract (1995); 2019 Aug; 47(3):105-110. PubMed ID: 31018721
[No Abstract] [Full Text] [Related]
18. Association between treatment of hepatitis C virus and risk of cardiovascular disease among insured patients with the virus in the United States.
Wang W; Chen C; Re VL; Chang SH; Wilson DL; Park H
Pharmacoepidemiol Drug Saf; 2023 Oct; 32(10):1142-1151. PubMed ID: 37278688
[TBL] [Abstract][Full Text] [Related]
19. Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations.
Rossi C; Jeong D; Wong S; McKee G; Butt ZA; Buxton J; Wong J; Darvishian M; Bartlett S; Samji H; Yu A; Binka M; Alvarez M; Adu PA; Tyndall M; Krajden M; Janjua NZ;
J Hepatol; 2019 Dec; 71(6):1116-1125. PubMed ID: 31433302
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population.
Sikavi C; Chen PH; Lee AD; Saab EG; Choi G; Saab S
Hepatology; 2018 Mar; 67(3):847-857. PubMed ID: 29108121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
